American Century Companies Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 4.7% in the fourth quarter, HoldingsChannel reports. The firm owned 58,153 shares of the biopharmaceutical company’s stock after acquiring an additional 2,588 shares during the period. American Century Companies Inc.’s holdings in Ultragenyx Pharmaceutical were worth $2,528,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of RARE. Norges Bank purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $16,047,000. D. E. Shaw & Co. Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 5,859.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 321,834 shares of the biopharmaceutical company’s stock worth $13,993,000 after purchasing an additional 316,434 shares in the last quarter. Macquarie Group Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $20,045,000. First Trust Advisors LP increased its stake in shares of Ultragenyx Pharmaceutical by 16.5% during the 4th quarter. First Trust Advisors LP now owns 1,471,934 shares of the biopharmaceutical company’s stock worth $64,000,000 after purchasing an additional 208,468 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 2.8% during the 4th quarter. BlackRock Inc. now owns 4,476,812 shares of the biopharmaceutical company’s stock worth $194,652,000 after purchasing an additional 123,409 shares in the last quarter. 98.59% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on RARE shares. Wedbush reissued an “outperform” rating and set a $88.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 7th. Cowen restated a “buy” rating and set a $69.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 26th. Raymond James restated an “outperform” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 22nd. Credit Suisse Group restated a “hold” rating and set a $59.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 20th. Finally, BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $76.84.
In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 18th. The shares were sold at an average price of $70.00, for a total value of $1,036,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 8.40% of the stock is owned by company insiders.
Shares of NASDAQ RARE opened at $72.26 on Tuesday. Ultragenyx Pharmaceutical Inc has a 1 year low of $37.44 and a 1 year high of $90.98. The company has a market cap of $3.67 billion, a P/E ratio of -9.78 and a beta of 2.22.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.01. The firm had revenue of $16.26 million for the quarter, compared to analyst estimates of $13.30 million. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. Analysts forecast that Ultragenyx Pharmaceutical Inc will post -6.71 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://transcriptdaily.com/2019/04/16/american-century-companies-inc-acquires-2588-shares-of-ultragenyx-pharmaceutical-inc-rare.html.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.